This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Opdivo
  • /
  • Nivolumab Combined With Ipilimumab Versus Sunitini...
Clinical trial

Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)

Read time: 2 mins
Last updated:1st Oct 2014
Identifier: NCT02231749

The purpose of this study is to compare the objective response rate, progression free survival and the overall survival of Nivolumab combined with Ipilimumab to Sunitinib monotherapy in patients with previously untreated Renal Cell Cancer.


Study Type: Interventional  (Clinical Trial)
Actual Enrollment: 1407 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Ipilimumab Versus Sunitinib Monotherapy in Subjects With Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma
Actual Study Start Date: October 13, 2014
Actual Primary Completion Date: June 26, 2017
Estimated Study Completion Date: September 30, 2019

Arms:
- Experimental:
Arm A: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg
- Active Comparator: Arm B: Sunitinib 50 mg

Category Value
Date last updated at source 2017-08-17
Study type(s) Interventional
Expected enrolment 1070
Study start date 2014-10-01

View full details